LABORATORY RESEARCH
A Critical Role of Integrin-Linked Kinase, ch-TOG and TACC3 in Centrosome Clustering in Cancer Cells
In this study, researchers demonstrate that the integrin-linked kinase, a protein critically involved in actin and mitotic microtubule organization, is required for centrosome clustering. [Oncogene]
Knockdown of Inwardly Rectifying Potassium Channel Kir2.2 Suppresses Tumorigenesis by Inducing ROS-Mediated Cellular Senescence
In the present study, researchers demonstrate that knockdown of the inwardly rectifying K+ channel Kir2.2 induced growth arrest without additional cellular stress in cancer cells lacking functional p53, p16, and/or Rb. Kir2.2 knockdown also induced senescence-associated beta-galactosidase activity and up-regulated senescence marker proteins in multiple cancer cell lines derived from different tissues, including prostate, stomach, and breast. [Mol Cancer Ther]
Secretory Phospholipase A2-IIa is Involved in Prostate Cancer Progression and May Potentially Serve as a Biomarker for Prostate Cancer
Here, researchers found that secretory phospholipase A2-IIa is overexpressed in androgen-independent prostate cancer LNCaP-AI cells relative to their androgen-dependent LNCaP cell counterparts. [Carcinogenesis]
A Dietary Tomato Supplement Prevents Prostate Cancer in TRAMP Mice
Transgenic adenocarcinoma of the mouse prostate (TRAMP) is a model for progressive prostate cancer that mirrors the stages of the human form. In this study, the effects of a diet enriched with processed whole tomatoes on survival, tumorigenesis, and progression of prostate cancer, and the antioxidant and inflammatory status of TRAMP mice were investigated. [Cancer Prev Res]
Comparison of Methyl-DNA Immunoprecipitation (MeDIP) and Methyl-CpG Binding Domain (MBD) Protein Capture for Genome-Wide DNA Methylation Analysis Reveal CpG Sequence Coverage Bias
In this study, researchers compared two commonly used approaches to enrich for methylated DNA regions of the genome, namely methyl-DNA immunoprecipitation that is based on enrichment with antibodies specific for 5′-methylcytosine, and capture of methylated DNA using a methyl-CpG binding domain-based protein to discover differentially methylated regions in cancer. [Epigenetics]
Molecular Decoy to the Y-Box Binding Protein-1 Suppresses the Growth of Breast and Prostate Cancer Cells whilst Sparing Normal Cell Viability
The data collectively suggest that the cell permeable peptide (CPP) is a novel approach to suppressing the growth of cancer cells while sparing normal cells and thereby establishes a proof-of-concept that blocking Y-box binding protein-1 activation is a new course of cancer therapeutics. [PLoS ONE]
Hypoxia-Selective Growth Inhibition of Cancer Cells by Furospinosulin-1, a Furanosesterterpene Isolated from an Indonesian Marine Sponge
Furospinosulin-1, a marine-sponge-derived furanosesterterpene, exhibited selective antiproliferative activity against DU145 human prostate cancer cells under hypoxic conditions in concentrations ranging from 1 to 100 micromolar. [ChemMedChem]
Prostate Specific Antigen Concentration at Age 60 and Death or Metastasis from Prostate Cancer: Case-Control Study
The objective of this study was to determine the relation between concentrations of prostate specific antigen at age 60 and subsequent diagnosis of clinically relevant prostate cancer in an unscreened population to evaluate whether screening for prostate cancer and chemoprevention could be stratified by risk. [Br Med J]
Balancing the Harms and Benefits of Early Detection of Prostate Cancer
For men with a low serum prostate-specific antigen level, the benefits of aggressive investigation and treatment may be limited because they are associated with a large increase in cumulative incidence and potential overtreatment. [Cancer]
Serum miRNA-21: Elevated Levels in Patients with Metastatic Hormone-Refractory Prostate Cancer and Potential Predictive Factor for the Efficacy of Docetaxel-Based Chemotherapy
miR-21 has been recognized as an “onco-microRNA” with the activity of negatively modulating the expression of tumor-suppressor genes. However, its role in prostate cancer (CaP) has not been well-documented. Researchers designed this study to assess the potential function of serum miR-21 in the progression of CaP. [Prostate]
|
INDUSTRY NEWS
Maryland Stem Cell Research Commission to Host Third Annual Maryland Stem Cell Research Symposium
The Maryland Stem Cell Research Commission will host the Third Annual Maryland Stem Cell Research Symposium in partnership with the National Institutes of Health and the National Institute of Standards and Technology on Sept. 22, 2010. [The Maryland Stem Cell Research Commission Press Release]
The Karmanos Cancer Center One of the First in Michigan to use PROVENGE, the New FDA-Approved Drug for Advanced Prostate Cancer
The Barbara Ann Karmanos Cancer Center in Detroit was recently selected to be one of 50 sites in the United States to offer the new U.S. Food and Drug Administration (FDA)-approved drug PROVENGE® (sipuleucel-T) to treat patients with advanced metastatic prostate cancer. [Barbara Ann Karmanos Cancer Center Press Release]
GTx Announces That GTx-758, a Novel Oral Selective Estrogen Receptor Alpha Agonist Being Developed to Treat Advanced Prostate Cancer, Induced Medical Castration in a Phase II PK/PD Clinical Trial
GTx, Inc. announced that in a Phase II, open label, pharmacokinetic-pharmacodynamic clinical trial, GTx-758, an oral selective estrogen receptor alpha agonist being developed to treat advanced prostate cancer, suppressed serum total testosterone to castrate levels, increased serum SHBG (sex hormone binding globulin), and markedly reduced serum free testosterone in healthy male volunteers. [GTx, Inc. Press Release]
|
POLICY NEWS
NIH Expands Network Focused on How Genes Affect Drug Responses [National Institutes of Health, United States]
National Institute of Biomedical Imaging and Bioengineering; Notice of Closed Meeting (FR Doc. 2010-22327) [National Institutes of Health, United States]
National Center for Research Resources; Notice of Closed Meetings (FR Doc. 2010-22529) [National Institutes of Health, United States]
Notice of Correction: Application Due Date for RFA-HG-10-012, Revolutionary Genome Sequencing Technologies – The $1000 Genome (R01) and RFA-HG-10-013, Revolutionary Genome Sequencing Technologies – The $1000 Genome (R21) (Notice Number:NOT-HG-10-021) [National Institutes of Health, United States]
Knockout Mouse Production and Cryopreservation (U42) (RFA-RM-10-013) [National Institutes of Health, United States]
Knockout Mouse Phenotyping Project Database (U54) (RFA-RM-10-012) [National Institutes of Health, United States]
Knockout Mouse Phenotyping (U54) (RFA-RM-10-011) [National Institutes of Health, United States]
Enhancing Peer Review: Reminder of and Correction to Previous Notice on A2 Resubmission Opportunities for Eligible Applications (NOT-OD-10-135) [National Institutes of Health, United States]
Notice of Correction to RFA-AG-11-010, Basic Research on Self-Regulation (R21) (NOT-AG-10-011) [National Institutes of Health, United States]
|
EVENTS (Listed by Date)
2010 Prostate Cancer Canada (PCCN) Conference
September 22-25, 2010
Toronto, Canada
International Society for Cellular Therapy 2nd Annual Symposium on Stem Cell Translation: Best Practices & Regulatory Considerations
September 27-28, 2010
San Francisco, United States
35th European Society for Medical Oncology (ESMO) Congress
October 8-12, 2010
Milan, Italy
NEW American Association for Cancer Research (AACR) Translational Cancer Research for Basic Scientists
October 17-22, 2010
Boston, United States
Frontiers in Tumour Progression
October 24-27, 2010
Madrid, Spain
NEW Ninth Annual American Association for Cancer Research (AACR) International Conference on Frontiers in Cancer Prevention Research
November 7-10, 2010
Philadelphia, United States
Cancer Pharmacogenetics: Personalising Medicine
November 22-24, 2010
Madrid, Spain
NEW The 10th Annual Meeting of the Society Of Urologic Oncology (SUO) – 10th Annual Winter Meeting
December 3-5, 2010
Bethesda, United States
NEW American Association for Cancer Research (AACR) Stem Cells, Development, and Cancer
March 3-6, 2011
Vancouver, Canada
IMPaCT: Innovative Minds in Prostate Cancer Today 2011
March 9-12, 2011
Orlando, United States
NEW American Association for Cancer Research (AACR) 102nd Annual Meeting 2011
April 2-6, 2011
Orlando, United States
NEW American Association for Cancer Research (AACR) Cancer Research Imaging Camp
June 19-24, 2011 St. Louis, United States |
|
|
Cancer Stem Cell News
Cell Therapy News
Dermal Cell News
Endothelial Cell News
ESC & iPSC News
Extracellular Matrix News
Hematopoiesis News
Hepatic Cell News
Human Immunology News
Immune Regulation News
Intestinal Cell News
Mammary Cell News
Mesenchymal Cell News
Muscle Cell News
Neural Cell News
Organoid News
Pancreatic Cell News
Prostate Cell News
Pulmonary Cell News
